Results 211 to 220 of about 1,829,207 (256)

Dissociable Handwriting Domains in Parkinson's Disease?

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Handwriting abnormalities in Parkinson's disease (PD) extend beyond classical micrographia and may involve multiple graphomotor domains with distinct clinical and mechanistic correlates. Objectives To investigate whether distinct handwriting domains demonstrate dissociable relationships with differential diagnostic performance ...
Beyza Nur Cetin   +3 more
wiley   +1 more source

JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link?

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Elena Ardila Jurado   +5 more
wiley   +1 more source

Validation of the Telephone MoCA in iRBD and Parkinson's Disease with Conversion to the Standard MoCA

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Telephone‐based cognitive assessment may improve follow‐up when face‐to‐face testing is impractical. The Telephone Montreal Cognitive Assessment (T‐MoCA) omits visually dependent items from the standard MoCA, but its validity in isolated REM sleep behavior disorder (iRBD) and Parkinson's disease (PD), remains uncertain.
Ludo van Hillegondsberg   +7 more
wiley   +1 more source

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota   +14 more
wiley   +1 more source

Aerobic exercise for substance use disorders: therapeutic effects and underlying mechanisms. [PDF]

open access: yesFront Med (Lausanne)
Liu QQ   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy